Published in AIDS Weekly, July 10th, 1995
E. Aguilar-Cordova and colleagues, Baylor College of Medicine, Houston, Texas, said that they constructed a double transdominant fusion gene (trev) that was designed to inhibit simultaneously two essential HIV functions ("Inhibition of HIV-1 by a Double Transdominant Fusion Gene," Gene Therapy, 1995;2:181-186). This was achieved by linking tat and rev transdominant mutants.
"Trev independently inhibited both Tat and Rev functions, localized within the nucleus and cells transfected with trev...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.